{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:09:33Z","timestamp":1740172173809,"version":"3.37.3"},"reference-count":14,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,2,20]],"date-time":"2017-02-20T00:00:00Z","timestamp":1487548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2017,2,20]],"date-time":"2017-02-20T00:00:00Z","timestamp":1487548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacol Res Perspect"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1002\/prp2.286","type":"journal-article","created":{"date-parts":[[2017,2,20]],"date-time":"2017-02-20T06:46:40Z","timestamp":1487573200000},"page":"e00286","source":"Crossref","is-referenced-by-count":16,"title":["A phase 1 study comparing the proposed biosimilar BS-503a with bevacizumab in healthy male volunteers"],"prefix":"10.1002","volume":"5","author":[{"given":"Naoyuki","family":"Tajima","sequence":"first","affiliation":[{"name":"Daiichi Sankyo Co., Ltd.; 1-2-58 Hiromachi Shinagawa-ku Tokyo 140-8710 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Martinez","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Development Ltd.; Chiltern Place, Chalfont Park Gerrards Cross SL9 0BG United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiaki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd.; 1-2-58 Hiromachi Shinagawa-ku Tokyo 140-8710 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"He","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Pharma Development; 399 Thornall Street Edison New Jersey 08837"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Dewland","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Development Ltd.; Chiltern Place, Chalfont Park Gerrards Cross SL9 0BG United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,2,20]]},"reference":[{"issue":"5 Suppl 16","key":"10.1002\/prp2.286-BIB0001|prp2286-cit-0001","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.seminoncol.2003.08.013","article-title":"A phase I\/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer","volume":"30","author":"Cobleigh","year":"2003","journal-title":"Semin Oncol"},{"volume-title":"Guideline on similar biological medicinal products","year":"2014","author":"Committee for Medicinal Products for Human Use (CHMP)","key":"10.1002\/prp2.286-BIB0002|prp2286-cit-0002"},{"key":"10.1002\/prp2.286-BIB0003|prp2286-cit-0003","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1208\/s12248-014-9581-z","article-title":"Development of a method that eliminates false-positive results due to nerve growth factor interference in the assessment of fulranumab immunogenicity","volume":"16","author":"Dai","year":"2014","journal-title":"AAPS J"},{"volume-title":"Avastin [summary of product characteristics]","year":"2014","author":"EMA","key":"10.1002\/prp2.286-BIB0004|prp2286-cit-0004"},{"key":"10.1002\/prp2.286-BIB0005|prp2286-cit-0005","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"10.1002\/prp2.286-BIB0006|prp2286-cit-0006","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"volume-title":"Avastin [highlights of prescribing information]","year":"2013","author":"Food and Drug Administration","key":"10.1002\/prp2.286-BIB0007|prp2286-cit-0007"},{"issue":"4 Suppl 3","key":"10.1002\/prp2.286-BIB0008|prp2286-cit-0008","first-page":"7","article-title":"Antiangiogenic therapy for cancer: current and emerging concepts","volume":"19","author":"Jain","year":"2005","journal-title":"Oncology (Williston Park)"},{"key":"10.1002\/prp2.286-BIB0009|prp2286-cit-0009","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00280-007-0664-8","article-title":"Clinical pharmacokinetics of bevacizumab in patients with solid tumors","volume":"62","author":"Lu","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/prp2.286-BIB0010|prp2286-cit-0010","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(84)91816-6","article-title":"Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration","volume":"1","author":"Marshall","year":"1984","journal-title":"Lancet"},{"key":"10.1002\/prp2.286-BIB0011|prp2286-cit-0011","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1161\/HYPERTENSIONAHA.111.00841","article-title":"Role of endogenous vascular endothelial growth factor in endothelium-dependent vasodilation in humans","volume":"61","author":"Thijs","year":"2013","journal-title":"Hypertension"},{"volume-title":"Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product","year":"2012","author":"US Department of Health and Human Services","key":"10.1002\/prp2.286-BIB0012|prp2286-cit-0012"},{"volume-title":"Guidance for industry: clinical pharmacology data to support a demonstration of biosimilarity to a reference product","year":"2014","author":"U.S. Department of Health and Human Services","key":"10.1002\/prp2.286-BIB0013|prp2286-cit-0013"},{"key":"10.1002\/prp2.286-BIB0014|prp2286-cit-0014","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00280-011-1606-z","article-title":"A multicenter, randomized, open-label study to access the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer","volume":"68","author":"Zhi","year":"2011","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Pharmacology Research & Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fprp2.286","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/prp2.286\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T05:00:05Z","timestamp":1625461205000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/prp2.286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,20]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"URL":"https:\/\/doi.org\/10.1002\/prp2.286","archive":["Portico"],"relation":{},"ISSN":["2052-1707"],"issn-type":[{"type":"print","value":"2052-1707"}],"subject":[],"published":{"date-parts":[[2017,2,20]]}}}